Los Angeles Capital Management LLC Sells 1,009 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Los Angeles Capital Management LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 49.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,013 shares of the company’s stock after selling 1,009 shares during the period. Los Angeles Capital Management LLC’s holdings in IDEXX Laboratories were worth $419,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of IDXX. Flossbach Von Storch SE raised its stake in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after acquiring an additional 464,791 shares during the period. Assenagon Asset Management S.A. grew its holdings in IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd bought a new position in IDEXX Laboratories during the 4th quarter valued at about $113,104,000. Vontobel Holding Ltd. lifted its stake in IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after purchasing an additional 198,404 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT boosted its position in shares of IDEXX Laboratories by 2,000.7% during the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 88,713 shares of the company’s stock valued at $36,678,000 after buying an additional 84,490 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Up 0.0 %

Shares of IDEXX Laboratories stock opened at $437.15 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market cap of $35.55 billion, a price-to-earnings ratio of 40.97, a PEG ratio of 3.41 and a beta of 1.37. The firm’s 50-day moving average is $435.79 and its two-hundred day moving average is $450.78. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $580.18.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.